Administration of liposome-derived cGAMP nanoparticles (cGAMP-NP) to tumor cells can activate STING in macrophages, repolarize M2-type macrophages into M1-type macrophages, improve MHC-like molecules or costimulatory molecules, and then induce differentiation of CD4+ and CD8+ T cells, thus producing a potent antitumor response (50). This evidence concerns the gene CD4 and neoplasm.